Speaking of valuation of for the company we should remember how much Takeda paid for Tigenix acquisition in 2018. I think once the global interest rates rises start to settle ( and hopefully come down) and valuation game comes into play , mesoblast would be very cheap at these rates. In the meantime company should try and focus to get at least one indication over the line which FDA has set( even if it requires some partnerships/ selling some assets). Surely Silviu and team do understand this. Ofcourse the downside risk is FDA doesn`t let mesoblast over the line , which I believe is a possibility and most investors clearly understand.
https://www.pharmaceutical-technology.com/news/takeda-tigenix-acquisition-608m/
Ann: Mesoblast Type A Meeting with FDA, page-229
-
- There are more pages in this discussion • 346 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
0.025(2.70%) |
Mkt cap ! $1.084B | |||
| Open | High | Low | Value | Volume |
| 94.0¢ | 96.8¢ | 93.5¢ | $4.207M | 4.417M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 42268 | 94.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 95.0¢ | 48002 | 3 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |